| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V97418 | AJI-214 | 1395886-20-0 | AJI-214 is a dual-target inhibitor of Aurora Kinase A and JAK2. It inhibits T cell mitosis and cell polarity by directly blocking Aurora Kinase A, and inhibits STAT3 phosphorylation by inhibiting JAK2 activation, thereby reducing TH1 and TH17 cell differentiation. It can be used to regulate immune responses and prevent graft-versus-host disease (GVHD). |
|
V0365 | AMG-900 | 945595-80-2 | AMG 900 (AMG-900), a phtha-lazinamine compound,is a novel and ATP-competitive pan-Aurora (A/B/C) kinase inhibitor with potential antitumor activity. |
|
V88590 | AurkA allosteric-IN-1 | AurkA allosteric-IN-1 (compound 6h) is an Aurora A (AurkA) inhibitor (IC50: 6.50 μM), which inhibits the catalytic activity and non-catalytic functions of Aurora A. | |
|
V129657 | Aurora kinase inhibitor-13 | 792965-51-6 | Aurora kinase inhibitor-13 is an inhibitor of Aurora kinase with an IC50 value of 2.3 μM for Aurora kinase A. |
|
V111345 | Aurora kinase/HDAC-IN-1 | 2727102-12-5 | Aurora kinase/HDAC-IN-1 is an orally effective dual-target inhibitor of Aurora kinase and HDAC, which inhibits Aurora A (IC50 = 116 nM), Aurora B (IC50 = 225 nM), HDAC1 (IC50 = 164 nM) and HDAC2 (IC50 = 346 nM). |
|
V4055 | Aurora Kinase Inhibitor III | 879127-16-9 | Aurora kinase inhibitor III, a 2,4-dianilinopyrimidine compound, is a novel, potent, highly selective, cell-permeable and ATP-competitive inhibitor of aurora related kinase (ARK) with IC50 of 42 nM for Aurora A kinase. |
|
V0350 | BI-847325 | 1207293-36-4 | BI-847325 (BI847325) is a novel, potent, orally bioavailable, and selective dual inhibitor of MEK (mitogen-activated protein kinase kinase) and Aurora kinase with potential antitumor activity. |
|
V131197 | CCG 224061 | 2055990-82-2 | CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.066 μM. |
|
V131198 | CCG 258001 | 2055990-96-8 | CCG 258001 is a GRK inhibitor with IC50 values of 0.29, 51.8 and 33 µM for GRK2, GRK1 and GRK5, respectively. |
|
V0356 | CCT137690 | 1095382-05-0 | CCT137690 is a novel, potent, highly selective andorally bioavailable inhibitor of Aurora kinase A/B/C with potential antitumor activity. |
|
V0359 | CCT129202 | 942947-93-5 | CCT129202 (CCT-129202), animidazopyridine compound,is a potent andATP-competitive pan-Aurora inhibitor with potential antitumor activity. |
|
V0364 | CYC116 | 693228-63-6 | CYC116 is a novel, potent, orally bioavailable inhibitor of Aurora A/B/C kinases with potential antitumor activity. |
|
V0363 | ENMD-2076 | 934353-76-1 | ENMD-2076 (ENMD2076) is a novel,potent andorally bioactive inhibitor of multikinase including Aurora A and Flt3 with potential antitumor activity. |
|
V136935 | GRK6-IN-4 | 300731-73-1 | GRK6-IN-4 is a G protein-coupled receptor 6 kinase (GRK6) inhibitor with an IC50 of 1.56 μM. |
|
V136936 | GRK6-IN-5 | 33495-39-5 | GRK6-IN-5 is a GRK6 peptide inhibitor with an IC50 value of 4.48 μM. |
|
V0355 | GSK1070916 (NMI900 or GSK1070916 A) | 942918-07-2 | GSK1070916 (also known as NMI-900 or GSK-1070916A)is a novel, potent, reversible and ATP-competitive inhibitor of Aurora B/C with potential antitumor activity. |
|
V0353 | KW-2449 | 1000669-72-6 | KW-2449 (KW2449) is a novel, potent, multiple-kinase (e. |
|
V0357 | MK-5108 (VX689) | 1010085-13-8 | MK-5108 (also known as VX-689)is a novel, specific and ATP-competitive inhibitor of Aurora A kinase with potential anticancer activity. |
|
V0352 | MK-8745 | 885325-71-3 | MK-8745 is a novel, potent, specific and selective Aurora A inhibitor with potential antitumor activity. |
|
V0347 | MLN8054 | 869363-13-3 | MLN-8054 (MLN8054), abenzazepine-based compound, is a selective, and ATP-competitive inhibitor of Aurora A kinase (AAK) with potential antitumor activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
